|
1
|
Stahl M, Stuschke M, Lehmann N, et al:
Chemoradiation with and without surgery in patients with locally
advanced squamous cell carcinoma of the esophagus. J Clin Oncol.
23:2310–2317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bedenne L, Michel P, Bouché O, et al:
Chemoradiation followed by surgery compared with chemoradiation
alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol.
25:1160–1168. 2007. View Article : Google Scholar
|
|
3
|
Bonnetain F, Bouché O, Michel P, et al: A
comparative longitudinal quality of life study using the Spitzer
quality of life index in a randomized multicenter phase III trial
(FFCD 9102): chemoradiation followed by surgery compared with
chemoradiation alone in locally advanced squamous resectable
thoracic esophageal cancer. Ann Oncol. 17:827–834. 2006.
|
|
4
|
McNamara MJ and Adelstein DJ: Current
Developments in the management of locally advanced esophageal
cancer. Curr Oncol Rep. 14:342–349. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gotoh M, Takiuchi H, Kawabe S, et al:
Epidermal growth factor receptor is a possible predictor of
sensitivity to chemoradiotherapy in the primary lesion of
esophageal squamous cell carcinoma. Jpn J Clin Oncol. 37:652–657.
2007. View Article : Google Scholar
|
|
6
|
Yamamoto Y, Yamai H, Seike J, et al:
Prognosis of esophageal squamous cell carcinoma in patients
positive for human epidermal growth factor receptor family can be
improved by initial chemotherapy with docetaxel, fluorouracil, and
cisplatin. Ann Surg Oncol. 19:757–765. 2012. View Article : Google Scholar
|
|
7
|
Lee JM, Yang SY, Yang PW, et al:
Polymorphism in epidermal growth factor receptor intron 1 predicts
prognosis of patients with esophageal cancer after chemoradiation
and surgery. Ann Surg Oncol. 18:2066–2073. 2011. View Article : Google Scholar
|
|
8
|
Kawaguchi Y, Kono K, Mimura K, et al:
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated
immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer.
97:494–501. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Itakura Y, Sasano H, Shiga C, et al:
Epidermal growth factor receptor overexpression in esophageal
carcinoma. An immunohistochemical study correlated with
clinicopathologic findings and DNA amplification. Cancer.
74:795–804. 1994. View Article : Google Scholar
|
|
10
|
Gibault L, Metges JP, Conan-Charlet V, et
al: Diffuse EGFR staining is associated with reduced overall
survival in locally advanced oesophageal squamous cell cancer. Br J
Cancer. 93:107–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu WW, Guo YM, Zhu M, et al:
Clinicopathological and prognostic significance of EGFR
over-expression in esophageal squamous cell carcinoma: a
meta-analysis. Hepatogastroenterology. 58:426–431. 2011.PubMed/NCBI
|
|
12
|
Sarbia M, Ott N, Pühringer-Oppermann F and
Brücher BL: The predictive value of molecular markers (p53, EGFR,
ATM, CHK2) in multimodally treated squamous cell carcinoma of the
oesophagus. Br J Cancer. 97:1404–1408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Minsky BD, Pajak TF, Ginsberg RJ, et al:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: high-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002. View Article : Google Scholar
|
|
14
|
Yang YL, Xu KL, Zhou Y, et al: Correlation
of epidermal growth factor receptor overexpression with increased
epidermal growth factor receptor gene copy number in esophageal
squamous cell carcinomas. Chin Med J (Engl). 125:450–454.
2012.PubMed/NCBI
|
|
15
|
Hanawa M, Suzuki S, Dobashi Y, et al: EGFR
protein overexpression and gene amplification in squamous cell
carcinomas of the esophagus. Int J Cancer. 118:1173–1180. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sunpaweravong P, Sunpaweravong S,
Puttawibul P, et al: Epidermal growth factor receptor and cyclin D1
are independently amplified and overexpressed in esophageal
squamous cell carcinoma. J Cancer Res Clin Oncol. 131:111–119.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marx AH, Zielinski M, Kowitz CM, et al:
Homogeneous EGFR amplification defines a subset of aggressive
Barrett’s adenocarcinomas with poor prognosis. Histopathology.
57:418–426. 2010.PubMed/NCBI
|
|
18
|
Zhang G, Zhang Q, Zhang Q, et al:
Expression of nucleostemin, epidermal growth factor and epidermal
growth factor receptor in human esophageal squamous cell carcinoma
tissues. J Cancer Res Clin Oncol. 136:587–594. 2010. View Article : Google Scholar
|
|
19
|
Delektorskaya VV, Chemeris YG, Zavalishina
LE, et al: Squamous cell carcinoma of the esophagus: evaluation of
the status of epidermal growth factor receptors (EGFR and HER-2) by
immunohistochemistry and in situ hybridization. Bull Exp Biol Med.
149:615–620. 2010. View Article : Google Scholar
|
|
20
|
Fukai Y, Masuda N, Kato H, et al:
Correlation between laminin-5gamma2 chain and epidermal growth
factor receptor expression in esophageal squamous cell carcinomas.
Oncology. 69:71–80. 2005. View Article : Google Scholar
|
|
21
|
Wang KL, Wu TT, Choi IS, et al: Expression
of epidermal growth factor receptor in esophageal and
esophagogastric junction adenocarcinomas: association with poor
outcome. Cancer. 109:658–667. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kii T, Takiuchi H, Kawabe S, et al:
Evaluation of prognostic factors of esophageal squamous cell
carcinoma (stage II–III) after concurrent chemoradiotherapy using
biopsy specimens. Jpn J Clin Oncol. 37:583–589. 2007.
|
|
23
|
Hironaka S, Ohtsu A, Boku N, et al:
Nonrandomized comparison between definitive chemoradiotherapy and
radical surgery in patients with T(2–3)N(any) M(0) squamous cell
carcinoma of the esophagus. Int J Radiat Oncol Biol Phys.
57:425–433. 2003.PubMed/NCBI
|
